论文部分内容阅读
由美国蛋白设计(PDL)公司创制、Hattmann-La Roche公司开发的人源化单克降抗体(McAb)与标准免疫抑制药一起使用时,可使肾移植患者的急性器官排斥反应降低40%.最近PDL和Roche公司对旨在预防肾移植患者急性移植物排斥反应的两项McAb(Zenapax)Ⅲ期试验结果进行了初步分析,500多名患者参与了这些试验.在第一项试验中,所有患者均接受环孢菌素和强的松的标准免疫抑制方案,其中半数患者还接受Zenapax.接受McAb的患者与未接受者相比,急性排斥反应降低40%.近半数仅接受免疫抑制药的患者发生急性排斥反应,而接受ZenaPax加免疫抑制药的患者仅28%发生急性排斥反应.第二项试验包括三种药物治疗加Zenapax.所有患者均接受环孢菌素、强的松和硫唑嘌呤.将Zenapax加入此方案后,急性排斥反应降低37%(无Zenapax组的发生率为35%,Zenapax组为22%).
Developed by the American Protein Design (PDL) company, the humanized monoclonal antibody McAb developed by Hattmann-La Roche, when used in combination with standard immunosuppressive drugs, can reduce acute organ rejection in renal transplant patients by 40%. Recently, PDL and Roche conducted a preliminary analysis of the results of the two Phase III trials of Zenapax aimed to prevent acute graft rejection in renal transplant recipients and more than 500 patients participated in these trials.In the first trial, all Patients received standard immunosuppressive regimens of cyclosporine and prednisone, and half of them also received Zenapax. Patients receiving McAb had a 40% reduction in acute rejection compared with those who did not. Nearly half of those who received only immunosuppressive drugs In patients with acute rejection, only 28% of patients receiving ZenaPax plus immunosuppressive drugs developed acute rejection and the second trial included three medications plus Zenapax.All patients received cyclosporine, prednisone and thiazole Purine After Zenapax was added to the regimen, the acute rejection rate was reduced by 37% (35% for the Zenapax group and 22% for the Zenapax group).